Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic acid added to neoadjuvant chemotherapy in osteosarcoma
ChiCTR-IPR-16008568Phase 4Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in osteosarcoma (OS) comparing Standard chemotherapy plus zoledronic acid with Standard chemotherapy plus placebo (2 arms). Primary endpoint: Progression-free survival. Started Jun 2016; status: recruiting.
02
Drugs
zoledronic acid
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on ChiCTR-IPR-16008568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-16008568.